Table 1 Osteoporosis features in the study analysis population as a function of diagnostic criterion for osteoporosis
From: Management of osteoporosis and associated quality of life in post menopausal women
|
Low BMD only N = 752 |
Fracture only N = 189 |
Both low BMD and fracture N = 365 | p |
Total N = 1,306 | |
|---|---|---|---|---|---|
|
Age at inclusion
(mean ± SD; years) |
N = 750
64.3 ± 8.4 |
N = 189
70.6 ± 9.6 |
N = 365
67.7 ± 8.671 | ≤ 0.001 |
N = 1304
66.2 ± 8.9 |
|
Age at menopause
(mean ± SD; years) |
N = 745
49.8 ± 4.0 |
N = 187
50.0 ± 3.6 |
N = 360
49.3 ± 4.3 | 0.218 |
N = 1290
49.7 ± 4.0 |
|
Time since menopause
(mean ± SD; years) |
N = 745
14.5 ± 8.7 |
N = 187
20.6 ± 9.5 |
N = 360
18.3 ± 9.9 | ≤ 0.001 |
N = 1290
16.5 ± 9.4 |
| At least one risk factor for osteoporosis | 564 (75.0%) | 156 (82.5%) | 308 (84.4%) | ≤ 0.001 | 1,028 (78.7%) |
| Osteoporosis treatment ongoing at time of consultation | 427 (56.8%) | 118 (62.4%) | 240 (65.8%) | 0.016 | 785 (60.1%) |
| Nature of ongoing treatment | N = 407 | N = 111 | N = 228 | N = 746 | |
| Bisphosphonates | 295 (72.5%) | 084 (75.7%) | 164 (71.9%) | 0.895 | 543 (72.8%) |
| Selective estrogen receptor modulator | 53 (13.0%) | 7 (6.3%) | 16 (7.0%) | 0.023 | 76 (10.2%) |
| Strontium ranelate | 54 (13.3%) | 18 (16.2%) | 47 (20.6%) | 0.062 | 119 (16.0%) |
| Other | 14 (3.5%) | 6 (5.4%) | 6 (2.7%) | 0.056 | 26 (3.5%) |
| Calcium or vitamin D supplementation |
N = 597
609 (82.3%) |
N = 153
161 (86.6%) |
N = 324
316 (87.8%) | 0.008 |
N = 1064
1086 (84.5%) |